This book is a compendium of the worldwide studies of gene therapy in neurologic conditions, that are registered with the United States National Institutes of Health website, clinicaltrials.gov. Clinicaltrials.gov is the largest listing of research studies in the world. The study titles are provided, as is the country of origin and the Clinical Trial Number in order to make it easier for the reader to locate the study and obtain further information. The book covers topics such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, Muscular Dystrophy, Frontotemporal Dementia, Epilepsy, and many more. Chapters will examine currently recruiting studies as well as soon-to-be recruiting studies.
Neurologic Gene Therapy: A Comprehensive Review of Global Clinical Trials will be a valuable resource for neurologists, neurosurgeons, related and allied physicians, PhDs, and researchers.
.
Chapter
1. Alzheimer's Disease.
.
Chapter
2. Adrenomyeloneuropathy.
.
Chapter
3. Astrocytoma.
.
Chapter
4. Batten Disease.
.
Chapter
5. Brain Tumors.
.
Chapter
6. Canavan Disease.
.
Chapter
7. Cerebral Adrenoleukodystrophy (CALD).
.
Chapter
8. Danon Disease.
.
Chapter
9. Epilepsy.
.
Chapter
10. Dravet Syndrome.
.
Chapter
11. Fabry's Disease.
.
Chapter
12. Friedreich's Ataxia.
.
Chapter
13. Frontotemporal Dementia.
.
Chapter
14. Gaucher Disease.
.
Chapter
15. Hearing Loss.
.
Chapter
16. Huntington's Disease.
.
Chapter
17. Krabbe Disease.
.
Chapter
18. Leber's Hereditary Optic Neuropathy.
.
Chapter
19. Multiple System Atrophy/Parkinson's.
.
Chapter
20. Muscular Dystrophy.
.
Chapter
21. Ornithine Transcarbamylase Deficiency.
.
Chapter
22. Pompe Disease.
.
Chapter
23. Rett Syndrome.
.
Chapter
24. Spinal Muscular Atrophy (SMA).
.
Chapter
25. Spastic Paraplegia Type 50 (SPG50).
.
Chapter
26. Wilson Disease.
Jeffrey N. Weiss, M.D., is the former Chief of Retinal Surgery at the Joslin Diabetes Center in Boston, Faculty of Harvard Medical School, and Visiting Scientist at the Massachusetts Institute of Technology.
Dr. Weiss is the author of more than 100 publications, including 28 books, holds more than 22 U.S. and foreign patents and has been a Reviewer for multiple scholarly journals. He has served as a Visiting Professor, performed surgery, and lectured both nationally and internationally. Dr. Weiss is also the founder of two companies, Ocular Research Associates Inc., and Micron Ophthalmic, Inc., which have manufactured and sold Dr. Weiss inventions worldwide.
Dr. Weiss was the first to invent the equipment and develop the technique to safely perform retinal vessel cannulation. This surgery remains the only option for patients with severe stroke in the eye. He was also the first to report the use of hyperbaric oxygen treatment to successfully treat dry age-related macular degeneration and longer standing central retinal artery occlusions.
Dr. Weiss performed the first retinal stem cell surgery in 2010, and is the Principal Investigator of The Stem Cell Ophthalmology Treatment Studies I/II, the largest retinal and optic nerve stem cell studies in the world, and The Neurologic Stem Cell Treatment Study. The studies are Institutional Review Board (IRB) approved, registered with NIH, and listed on ClinicalTrials.gov.
